MAPK3 and melanoma: Flow cytometry analyses revealed that the lal−/− MSC-CM treatment showed lower activation of ERK1/2, STAT3, and P38 in B16 melanoma cells compared with that in lal+/+ MSC-CM-treated B16 cells in syngeneic C57BL/6 mice (Figure 4B).